Aiming to alter the course of AD

Our lead candidate varoglutamstat is an orally administered small molecule inhibitor of glutaminyl cyclase (QPCT), an enzyme which catalyzes the formation of N3pE amyloid, a particularly neurotoxic molecule not found in healthy individuals that has been identified as a driver of Alzheimer’s disease (AD). Varoglutamstat is currently in Phase 2 clinical development.

Diverse pipeline addressing severe indications

We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings.


clinical Phase 2 trial with varoglutamstat in AD


years track-record of bringing own innovation from drug discovery into clinical trails


in vivo characterized small molecule QPCT/L inhibitors to target severe diseases


family of blockbuster diabetes drugs: gliptins, based on our research